Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Stephen_Brady
|
| gptkbp:collaboratesWith |
gptkb:Cancer_Research_UK
F. Hoffmann-La Roche Ltd |
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
oncology
immunotherapy |
| gptkbp:foundedYear |
2011
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tempest Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:pipeline |
TPST-1120
TPST-1495 TPST-217 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
TPST
|
| gptkbp:therapeuticArea |
gptkb:cancer
inflammatory diseases |
| gptkbp:website |
https://www.tempesttx.com/
|
| gptkbp:bfsParent |
gptkb:Tom_Dubensky
gptkb:Millendo_Therapeutics |
| gptkbp:bfsLayer |
7
|